[Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset].
Wilms' tumor gene WT1 mRNA is a new marker of leukemic blast cells for AML, ALL, and CML. Minimal residual disease(MRD) of leukemia can be detected at frequencies as low as 1 in 10(3) to 10(4) normal bone marrow cells and 1 in 10(5) normal peripheral blood mononuclear cells by means of the quantitation of WT1 mRNA(WT1 assay) using reverse transcriptase-polymerase chain reaction. Thus, the WT1 assay makes it possible to rapidly assess the effectiveness of treatment and to evaluate the degree of eradication of leukemic cell in individual leukemia patients. Furthermore, WT1 assay can continuously assess the disease progression of myelodysplastic syndromes(MDS) and predict the evolution of MDS to overt AML within 6 months.
Sugiyama
H
H
Department of Clinical Laboratory Science, Osaka University Medical School, Suita.
D004268:DNA-Binding Proteins / Q000235:genetics*; D016162:Genes, Wilms Tumor; D006801:Humans; D007938:Leukemia / Q000175:diagnosis* / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000175:diagnosis; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D012008:Recurrence; D014157:Transcription Factors / Q000235:genetics*; D025721:WT1 Proteins
D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D014157:Transcription Factors; D025721:WT1 Proteins